吡啶,5-(4-氟苯基)-2-甲基-,1-氧化 | 163211-74-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 吡啶,5-(4-氟苯基)-2-甲基-,1-氧化
• 英文名称: 5-(4-fluorophenyl)-2-methylpyridine-N-oxide
• 英文别名: 5-(4-fluorophenyl)-2-methyl-1-oxidopyridin-1-ium
• CAS: 163211-74-3
• 化学式: C₁₂H₁₀FNO
• 分子量: 203.216
• InChiKey: GWRFTOAMHQLFSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  25.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  吡啶,5-(4-氟苯基)-2-甲基-,1-氧化 在 乙酸酐 、 甲醇 、 potassium hydroxide 作用下， 反应 12.0h， 生成 5-(4-Fluorophenyl)pyridine-2-methanol
  参考文献：
  名称：

  Inhibition of 1-Deoxy-d-Xylulose-5-Phosphate Reductoisomerase by Lipophilic Phosphonates: SAR, QSAR, and Crystallographic Studies

  摘要：

  1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) is a novel target for developing new antibacterial (including antituberculosis) and antimalaria drugs. Forty-one lipophilic phosphonates, representing a new class of DXR inhibitors, were synthesized, among which 5-phenylpyridin-2-ylmethylphosphonic acid possesses the most activity against E. coli DXR (EcDXR) with a K-i of 420 nM. Structure-activity relationships (SAR) are discussed, which can be rationalized using our EcDXR:inhibitor structures, and a predictive quantitative SAR (QSAR) model is also developed. Since inhibition studies of DXR from Mycobacterium tuberculosis (MtDXR) have not been performed well, 48 EcDXR inhibitors with a broad chemical diversity were found, however, to generally exhibit considerably reduced activity against MtDXR. The crystal structure of a, MtDXR:inhibitor complex reveals the flexible loop containing the residues 198-208 has no strong interactions with the 3,4-dichlorophenyl group of the inhibitor, representing a structural basis for the reduced activity. Overall, these results provide implications in the future design and development of potent DXR inhibitors.

  DOI：

  10.1021/jm200363d
• 作为产物：
  描述：

  5-溴-2-甲基吡啶 在 四(三苯基膦)钯 、 sodium carbonate 、 间氯过氧苯甲酸 作用下， 以 氯仿 、 水 、 甲苯 为溶剂， 反应 5.0h， 生成 吡啶,5-(4-氟苯基)-2-甲基-,1-氧化
  参考文献：
  名称：

  Inhibition of 1-Deoxy-d-Xylulose-5-Phosphate Reductoisomerase by Lipophilic Phosphonates: SAR, QSAR, and Crystallographic Studies

  摘要：

  1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) is a novel target for developing new antibacterial (including antituberculosis) and antimalaria drugs. Forty-one lipophilic phosphonates, representing a new class of DXR inhibitors, were synthesized, among which 5-phenylpyridin-2-ylmethylphosphonic acid possesses the most activity against E. coli DXR (EcDXR) with a K-i of 420 nM. Structure-activity relationships (SAR) are discussed, which can be rationalized using our EcDXR:inhibitor structures, and a predictive quantitative SAR (QSAR) model is also developed. Since inhibition studies of DXR from Mycobacterium tuberculosis (MtDXR) have not been performed well, 48 EcDXR inhibitors with a broad chemical diversity were found, however, to generally exhibit considerably reduced activity against MtDXR. The crystal structure of a, MtDXR:inhibitor complex reveals the flexible loop containing the residues 198-208 has no strong interactions with the 3,4-dichlorophenyl group of the inhibitor, representing a structural basis for the reduced activity. Overall, these results provide implications in the future design and development of potent DXR inhibitors.

  DOI：

  10.1021/jm200363d

文献信息

• Isoquinolyl substituted hydroxylamine derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05334600A1

  公开（公告）日：1994-08-02

  The compounds of the formula ##STR1## wherein R represents hydrogen, lower alkyl, aryl, biaryl, C.sub.3 -C.sub.7 -cycloalkyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, aryloxy-lower alkyl, arylthio-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, biaryl-lower alkyl, aryl-C.sub.3 -C.sub.7 -cycloalkyl, aryl-C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl or aryloxy-aryl-lower alkyl; and aryl represents carbocyclic or heterocyclic aryl; Z represents C.sub.1 -C.sub.3 -alkylene or vinylene, each unsubstituted or substituted by lower alkyl; Y represents SO.sub.2 (sulfonyl) or CO (carbonyl); A represents .sub.0 (oxygen), S (sulfur), or a direct bond; B represents lower alkylene; or B represents lower alkenylene or lower alkynylene provided that A represents a direct bond; X represents oxygen or sulfur, R.sub.1 represents hydrogen, acyl, lower alkoxycarbonyl, aminocarbonyl, mono- or di-lower alkylaminocarbonyl, lower alkenylaminocarbonyl, lower alkynylaminocarbonyl, carbocyclic or heterocyclic aryl-lower alkylaminocarbonyl, carbocyclic or heterocyclic arylaminocarbonyl, C.sub.3 -C.sub.7 -cycloalkylaminocarbonyl or C.sub.3 -C.sub.7 -cycloalkyl-lower alkylaminocarbonyl; R.sub.2 represents lower alkyl, lower alkoxycarbonyl-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, carbocyclic or heterocyclic aryl, carbocyclic or heterocyclic aryl-lower alkyl, C.sub.3 -C.sub.7 -cycloaikyl-lower alkyl, amino, mono- or di-lower alkylamino, lower alkenylamino, lower alkynylamino, carbocyclic or heterocyclic aryl-lower alkylamino, carbocyclic or heterocyclic arylamino, C.sub.3 -C.sub.7 -cycloalkylamino, C.sub.3 -C.sub.7 -cycloalkyl-lower alkylamino or lower alkoxycarbonyl-lower alkylamino; R.sub.3 and R.sub.4 independently represent hydrogen or lower alkyl; R.sub.a represents hydrogen, lower alkyl, halo, trifluoromethyl or lower alkoxy; and pharmaceutically acceptable salts thereof; and their preparation and use as lipoxygenase inhibitors are described.

  该公式化合物的翻译如下：其中R代表氢、较低的烷基、芳基、联苯基、C.sub.3 -C.sub.7 -环烷基、芳基-较低烷基、芳基-较低烯基、芳基-较低炔基、芳氧基-较低烷基、芳硫基-较低烷基、C.sub.3 -C.sub.7 -环烷基-较低烷基、联苯基-较低烷基、芳基-C.sub.3 -C.sub.7 -环烷基、芳基-C.sub.3 -C.sub.7 -环烷基-较低烷基或芳氧基-芳基-较低烷基；芳基代表碳环芳基或杂环芳基；Z代表C.sub.1 -C.sub.3 -烷基或乙烯基，每个未被较低烷基取代；Y代表SO.sub.2（磺酰基）或CO（羰基）；A代表O（氧）、S（硫）或直接键；B代表较低烷基；或B代表较低烯基或较低炔基，前提是A代表直接键；X代表氧或硫；R.sub.1代表氢、酰基、较低烷氧羰基、氨基羰基、单-或双-较低烷基氨基羰基、较低烯基氨基羰基、较低炔基氨基羰基、碳环或杂环芳基-较低烷基氨基羰基、碳环或杂环芳基氨基羰基、C.sub.3 -C.sub.7 -环烷基氨基羰基或C.sub.3 -C.sub.7 -环烷基-较低烷基氨基羰基；R.sub.2代表较低烷基、较低烷氧羰基-较低烷基、C.sub.3 -C.sub.7 -环烷基、碳环或杂环芳基、碳环或杂环芳基-较低烷基、C.sub.3 -C.sub.7 -环烷基-较低烷基、氨基、单-或双-较低烷基氨基、较低烯基氨基、较低炔基氨基、碳环或杂环芳基-较低烷基氨基、碳环或杂环芳基氨基、C.sub.3 -C.sub.7 -环烷基氨基、C.sub.3 -C.sub.7 -环烷基-较低烷基氨基或较低烷氧羰基-较低烷基氨基；R.sub.3和R.sub.4独立地代表氢或较低烷基；R.sub.a代表氢、较低烷基、卤素、三氟甲基或较低烷氧基；以及其制备和用作脂氧酶抑制剂的药用盐。
• US5334600A
  申请人：——

  公开号：US5334600A

  公开（公告）日：1994-08-02
• Inhibition of 1-Deoxy-<scp>d</scp>-Xylulose-5-Phosphate Reductoisomerase by Lipophilic Phosphonates: SAR, QSAR, and Crystallographic Studies
  作者：Lisheng Deng、Jiasheng Diao、Pinhong Chen、Venugopal Pujari、Yuan Yao、Gang Cheng、Dean C. Crick、B. V. Venkataram Prasad、Yongcheng Song

  DOI：10.1021/jm200363d

  日期：2011.7.14

  1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) is a novel target for developing new antibacterial (including antituberculosis) and antimalaria drugs. Forty-one lipophilic phosphonates, representing a new class of DXR inhibitors, were synthesized, among which 5-phenylpyridin-2-ylmethylphosphonic acid possesses the most activity against E. coli DXR (EcDXR) with a K-i of 420 nM. Structure-activity relationships (SAR) are discussed, which can be rationalized using our EcDXR:inhibitor structures, and a predictive quantitative SAR (QSAR) model is also developed. Since inhibition studies of DXR from Mycobacterium tuberculosis (MtDXR) have not been performed well, 48 EcDXR inhibitors with a broad chemical diversity were found, however, to generally exhibit considerably reduced activity against MtDXR. The crystal structure of a, MtDXR:inhibitor complex reveals the flexible loop containing the residues 198-208 has no strong interactions with the 3,4-dichlorophenyl group of the inhibitor, representing a structural basis for the reduced activity. Overall, these results provide implications in the future design and development of potent DXR inhibitors.